Abstract
Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as a beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.
Keywords: Cyclooxygenase-2 (Cox-2), apoptosis, angiogenesis, cancer, prostaglandin, chemotherapy, radiotherapy, celecoxib, enzyme, arachidonic acid
Current Drug Targets
Title: Biology of Cox-2: An Application in Cancer Therapeutics
Volume: 12 Issue: 7
Author(s): Zakir Khan, Noor Khan, Ram P. Tiwari, Nand K. Sah, GBKS Prasad and Prakash S. Bisen
Affiliation:
Keywords: Cyclooxygenase-2 (Cox-2), apoptosis, angiogenesis, cancer, prostaglandin, chemotherapy, radiotherapy, celecoxib, enzyme, arachidonic acid
Abstract: Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Cox-2 in cancer cells. Elevated tumor Cox-2 is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. Several experimental and clinical studies have established potent anti-cancer activity of NSAID (Non-steroidal anti-inflammatory drugs) and other Cox-2 inhibitors such as celecoxib. Much attention is being focused on Cox-2 inhibitors as a beneficial target for cancer chemotherapy. The mode of action of Cox-2 and its inhibitors remains unclear. Further clinical application needs to be investigated for comprehending Cox-2 biological functions and establishing it as an effective target in cancer therapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Khan Noor, P. Tiwari Ram, K. Sah Nand, Prasad GBKS and S. Bisen Prakash, Biology of Cox-2: An Application in Cancer Therapeutics, Current Drug Targets 2011; 12 (7) . https://dx.doi.org/10.2174/138945011795677764
DOI https://dx.doi.org/10.2174/138945011795677764 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?
Current Drug Targets Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Carbon Nanofiber Reinforced Polycaprolactone Fibrous Meshes by Electrostatic Co-spinning
Current Nanoscience Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Current Pharmaceutical Design Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Exploring the Synthesis and Anticancer Potential of L-Tyrosine-Platinum(II) Hybrid Molecules
Medicinal Chemistry STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design Aberrant DNA Methylation and Prostate Cancer
Current Genomics New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry